ATHE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 112642 min ago

@ $1.920

Wydano: 14 vas. 2024 @ 22:33

Zwrot: 11.46%

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	39 951.00
Średni wolumen	87 016.00
Kapitalizacja rynkowa	19.97M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.050
ATR14	$0.0200 (0.93%)

Wolumen Korelacja

Długi: -0.25 (neutral)

Krótki: 0.87 (strong)

Signal:(49.509) Same movement expected

Alterity Therapeutics Korelacja

10 Najbardziej pozytywne korelacje
ZYXI	0.892
HAS	0.882
SNES	0.88
RUBY	0.876
PASG	0.875
SRTS	0.874
INTZ	0.872
SIGA	0.868
VNET	0.867
GETVV	0.867

10 Najbardziej negatywne korelacje
PLUS	-0.896
VCTR	-0.885
LOVE	-0.88
CRWD	-0.867
RDUS	-0.861
SHSP	-0.857
TVTY	-0.855
ZGNX	-0.852
TRNS	-0.847
PAE	-0.839

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alterity Therapeutics Korelacja - Waluta/Towar

-0.38
( neutral )

-0.55
( weak negative )

0.10
( neutral )

-0.43
( neutral )

-0.62
( weak negative )

0.26
( neutral )

Alterity Therapeutics Finanse

Annual	2023
Przychody:	$2.61M
Zysk brutto:	$2.51M (96.08 %)
EPS:	$-0.00570

FY	2023
Przychody:	$2.61M
Zysk brutto:	$2.51M (96.08 %)
EPS:	$-0.00570

FY	2022
Przychody:	$3.54M
Zysk brutto:	$3.29M (92.88 %)
EPS:	$-0.00530

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0541

Financial Reports:

No articles found.

Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.